Recent clinical studies in China and USA showed that arsenic trioxide (As 2 O 3 ) is an effective treatment of acute promyelocytic leukemia (APL) patients refractory to all-trans retinoic acid (RA). We here investigate the effects of As 2 O 3 on RA-resistant APL in vivo and in vitro using our RA-resistant APL model sys- 
Introduction
Acute promyelocytic leukemia (APL) is associated with a specific 15;17 translocation which generates a PML/RAR␣ fusion protein between the PML gene on chromosome 15 and the RAR␣ gene on chromosome 17.
1,2 PML/RAR␣ fusion protein has been proposed to block myeloid differentiation via inhibition of nuclear receptor response, and subsequently to be involved in the leukemogenesis of APL. 3, 4 Several clinical studies have shown that nearly all patients who are treated with all-trans retinoic acid (RA) achieve complete remission through an induction of differentiation of the leukemic cells. [5] [6] [7] [8] However, clinical remissions in patients treated with all-trans RA alone are usually of brief duration, and these patients often develop RA-resistant disease. 4 Recent clinical studies in China and USA have shown that As 2 O 3 is an effective treatment of even APL patients refractory to RA. 9, 10 to induce apoptosis of APL cell line NB4 cells, in association with the downregulation of bcl-2 gene expression and modulation of PML/RAR␣ chimeric protein. 11, 12 However, there have been no studies on As 2 O 3 using primary RA-resistant APL cells from patients in vitro or animal model in vivo. Therefore, it is important to establish an animal model of RA-resistant APL and to address the effects of As 2 O 3 on clinically acquired RA-resistant APL in vitro and in vivo.
We have recently established a novel APL cell line (UF-1) which was the first permanent cell line with spontaneous RAresistant features. 13 More recently, we established a human RA-resistant APL model in hGM-CSF-producing transgenic SCID mice using UF-1 cells. 14 In this study, we report that As 2 O 3 can induce apoptosis of RA-resistant APL both in vitro and in vivo, and also induce differentiation in vivo using our model system of APL.
Materials and methods

Cell cultures
The RA-resistant UF-1 promyelocytic leukemia cell line was established in our laboratory from a relapsed patient with APL who had received all-trans RA, 13 and the RA-sensitive NB4 promyelocytic cell line was a gift of Dr M Lanotte (Hô pital St Louis, Paris, France). 15 Cells were maintained in RPMI 1640 medium (GIBCO-BRL, Gaitherburg, MD, USA) with 10% FBS (Hyclone Laboratories, Logan, MT, USA), 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified atmosphere with 5% CO 2 . The morphology of the apoptotic cells was evaluated from cytospine slide preparations with Giemsa staining, and the viability was assessed by trypan blue dye exclusion.
Chemicals
As 2 O 3 was purchased from Sigma Chemical Co (St Louis, MO, USA) and dissolved with PBS to a stock concentration of 10
M. All-trans RA was purchased from Sigma and dissolved in 100% ethanol to a stock concentration of 1 mM, stored at −20°C, and protected from light.
Assays for cellular proliferation
Cellular proliferation was measured by a viability and a nonradioactive cell proliferation assay system (MTT assay; Boehringer Mannheim, Indianapolis, IN, USA). Cells were incubated with various concentrations of As 2 O 3 (0-2 M) for 4 days in 96-well plates (Flow Laboratories, Irvine, CA, USA). Ten l of MTT (5 g/ml) was added to each well. The reaction was stopped after 4 h of incubation by adding 100 l of 0.04 N HCl in isopropanol, and the OD 570 was determined.
Cell cycle analysis
Cells (1 × 10 6 ) were suspended in hypotonic solution (0.1% Triton X-100, 1 mM Tris-HCl (pH 8.0), 3.4 mM sodium citrate, 0.1 mM EDTA) and stained with 5 g/ml propidium iodide. Analysis was performed immediately after staining using the CELLFIT program (Becton Dickinson, Mountain View, CA, USA).
Flow cytometric analysis
Cells were incubated for 30 min with human AB serum (Sigma) to block Fc receptors and then were stained using PEconjugated mouse anti-human CD11b antibody (Becton Dickinson). Control studies were performed with non-binding control mouse IgG 1 and IgG 2a isotype antibodies (Becton Dickinson). Cells were analyzed by a Cytron Absolute Flow Cytometer (Ortho Diagnostic Systems, Raritan, NJ, USA).
DNA fragmentation
Cells (1 × 10 6 ) were washed with PBS, then incubated in lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM EDTA, 0.5% Triton X-100) at 4°C for 10 min. After centrifugation at 1600 g for 5 min at 4°C, supernatants were collected. RNase A (Sigma) was added to a final concentration at 50 g/ml, which was incubated for 2 h at 37°C. The cell lysate was then incubated overnight at 37°C with proteinase K (Sigma) at 100 g/ml. The DNA was extracted with phenol-chloroform, precipitated in ethanol, and centrifuged for 20 min at 1600 g. The DNA was then dissolved in TE buffer (10 mM Tris-HCl (pH 7.4), 1 mM EDTA) and separated on a 2% agarose gel. DNA fragments were visualized after ethidium bromide staining of the gel.
Western blotting
Cells were collected by centrifugation at 120 g for 10 min, and then the pellets were resuspended in lysis buffer (1% NP-40, 1 mM PMSF, 40 mM Tris-HCl (pH 8.0), 150 mM NaCl) at 4°C for 15 min. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad, Richmond, CA, USA). Cell lysates (10 g of protein per lane) were fractionated in 12.5% SDS-polyacrylamide gels prior to transfer to the membrane (Immobilon-P membranes; Millipore, Bedford, MA, USA) by standard protocol. The membrane was blocked overnight with 5% defatted milk in PBS at 4°C. The anti-BCL-2, and -BAX antibodies (Calbiochem, Cambridge, MA, USA) were used at 1:1000 dilution in 5% defatted milk in PBS for 1 h at 25°C. Subsequently, membranes were incubated with anti-rabbit Ig conjugated with horseradish peroxidase (1:3000; Amersham Japan, Tokyo, Japan) for 1 h at 25°C. All steps were followed by three washes for 5 min in PBS, 1% defatted milk, and 0.2% Tween 20. Antibody binding was detected by using the enhanced chemiluminescence kit for Western blotting detection with hyper-ECL film (Amersham). Blots were stained with Coomassie brilliant blue and confirmed to contain a similar amount of protein extract on each lane.
Animal studies
We have established a human GM-CSF-producing transgenic SCID (hGMTgSCID) mice system 16 and made the first human RA-resistant APL model in this SCID mice system by using UF-1 cells.
14 Briefly, mice were pretreated with 3 Gy of total body irradiation, a sublethal dose that was expected to enhance acceptance of xenografts. Subsequently, UF-1 cells (1 × 10 7 cells) in their logarithmic growth phase were inoculated subcutaneously into hGMTgSCID mice. Inoculated UF-1 cells formed subcutaneous tumors at the injection site, and cells grew rapidly. Forty days after implantation of the cells, 9.43 mg/kg body weight of As 2 O 3 (LD 50 of ICR mice) 9 were subcutaneously injected into the mice at separated site of tumors daily for 21 days. In addition, an all-trans RA pellet (25 mg/pellet, 21-day release; Innovative Research of America, Sarasota, FL, USA) was subcutaneously inoculated in the back of SCID mice, and effectively and continuously released active RA for 21 days in these animals. The tumor volume was measured every week. The volume measured on the first day of treatment was taken as 1.0, and changes in tumor size were expressed as a fold-increase of the initial tumor. When the mice showed severe wasting or observations were finished, mice were sacrificed according to the UKCCCR guidelines, and the day of sacrifice was recorded. 17 Tumors were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and then stained with hematoxylin and eosin for histological examination. Tumors were also frozen in OCT-compound for the immunohistochemical procedures. Antibodies used in this study were rabbit anti-human LCA and MPO polyclonal antibodies (DAKO Japan, Kyoto, Japan).
Results
Effects of As 2 O 3 on cellular proliferation of NB4 and UF-1 cells
As previously reported, 17 all-trans RA inhibited the cellular proliferation of NB4 cells in a dose-dependent manner ( Figure  1a) . Except under exposure to higher concentration of all-trans RA (10 −6 M), UF-1 cells did not suppress the absorbance of the MTT assay (Figure 1a ). In contrast, As 2 O 3 inhibited the cellular proliferation and decreased the number of viable cells of both RA-sensitive NB4 and RA-resistant UF-1 cells in a dose-dependent manner (Figure 1b and data not shown). UF-1 cells were slightly more sensitive to As 2 O 3 than NB4 cells. We next examined the effects of As 2 O 3 on the cell cycle progression in UF-1 cells and analyzed the cell cycle distribution by flow cytometry. Cultivation with 2 M As 2 O 3 for 72 h increased the proportion of UF-1 cells in the sub-G1 phase (apoptotic cells) from 0.1% to 89.1% with reduction of those in the S phase from 20.1% to 0.12% (Table 1) . 
As 2 O 3 induces apoptosis, but not differentiation of both NB4 and UF-1 cells
As 2 O 3 -induced apoptosis and differentiation in vivo
Our in vitro data prompted us to examine whether the effects of As 2 O 3 are valid in vivo. RA-resistant UF-1 cells were transplanted into hGMTgSCID mice. After 40 days of implantation, mice were treated with 9.43 mg/kg body weight As 2 O 3 , alltrans RA (21-day release, 25 mg/pellet) and PBS as a control for 21 days, and then the volume of subcutaneous tumor was measured every week ( Figure 6 ). In the PBS-treated control mice (n = 2) and all-trans RA-treated mice (n = 3), tumors grew as rapidly as in non-treated mice, with an estimated 4.5-fold increase in tumor volume between the first and 21st day of treatment (Figure 6 ). In contrast, the volume of tumors in the As 2 O 3 -treated mice (n = 4) decreased to about half of the initial size ( Figure 6 ). During the treatment, As 2 O 3 -treated mice appeared healthy and continued to eat. In addition, pathologic analysis at autopsy revealed no As 2 O 3 -induced tissue changes in all organs including liver. These results suggest that As 2 O 3 had no toxic effects on mice during the treatment.
At the 21st day of treatment in the animals treated with PBS
Leukemia
Figure 2
Morphological changes in NB4 and UF-1 cells by the treatment of As 2 O 3 . Cells were cultured with or without 1 M As 2 O 3 for 4 days, and cytospin slides were prepared and stained with Giemsa. Original magnification ×1000. and all-trans RA, expanded tumor masses of undifferentiated leukemic cells were present (Figure 7a-c) . The diminished tumors treated by As 2 O 3 showed the typical appearance of apoptosis, with condensed nuclei in the majority of cells (As 2 O 3 1) (Figure 7d-f) . Interestingly, tumor cells from one of the As 2 O 3 -treated mice (As 2 O 3 2) showed mature granulocytes (Figures 7g-i and 8a) . To discount the possibility of infiltration of mouse granulocytes due to the focal inflammation, we stained this tissue section with anti-human LCA and MPO antibodies (Figure 8b-e) . The spleen of PBS-treated control SCID mouse showed negative response to the antibodies for LCA and MPO (Figure 8d and e) , suggesting that these antibodies do not cross-react with cells from mouse tissues, and they react only with human tissues. Mature granulocytes in tumors of the As 2 O 3 -treated mice were positive for both antihuman LCA and MPO antibodies, suggesting that these cells were differentiated from the inoculated UF-1 cells, but were not originated from mouse tissues (Figure 8b and c) .
Discussion
We demonstrated in this report that As 2 O 3 can induce apoptosis of clinically acquired RA-resistant APL cells in vitro 
Figure 5
Western blot analysis of BCL-2 and BAX protein. Total cellular protein (10 g/lane) from UF-1 and NB4 cells treated for 24-48 h with 1 or 2 M As 2 O 3 was separated on a 12.5% SDS-polyacrylamide gel and transformed to the membrane. Protein levels were detected by Western blotting using antibodies directed against BCL-2 and BAX, and then the blot was stained with Coomassie Brilliant blue to confirm that equal amounts of protein were present in each lane.
and in vivo by using our established cell line and mice system. Recent clinical studies have shown that the optimal all-trans RA plus chemotherapy combination clearly indicates better results with complete remission and disease-free survival rates and a better control of both all-trans RA syndrome and coagulopathy. 18 Acquired resistance to all-trans RA will occur in patients following treatment with retinoid alone. 18, 19 Approximately 20-30% of patients treated with first-line approaches have been reported to relapse and relapsed APL patients more frequently show refractory disease or are short lived in second remission. [20] [21] [22] Therefore, clinical resistance to RA poses a serious problem for differentiation-inducing therapy. Recent clinical studies in China have shown that As 2 O 3 has been used as a traditional Chinese medicine to effectively treat APL for
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Figure 6
Effects of As 2 O 3 and all-trans RA on RA-resistant APL in vivo. Forty days after implantation of UF-1 cells (1 × 10 7 ) into hGM-CSF transgenic SCID mice, As 2 O 3 (9.43 mg/kg body weight) (n = 4), all-trans RA (21-day release pellet, 25 mg/pellet) (n = 3), and PBS (n = 2) were injected into separate sites of subcutaneous tumors. Total volumes were measured every week and changes in tumor size were expressed as a fold-increase of the initial tumor. Results are expressed as the mean ± s.d. of the experiments performed on separate mice. some 20 to 30 years. It has been reported that clinical complete remission was achieved in 65.6% to 84% cases of As 2 O 3 -treated APL in China. 9 Shen et al 9 showed that in 14 of 15 cases of APL that had relapsed after all-trans RA therapy, complete remission was induced and maintained by treatment with As 2 O 3 alone, suggesting no cross-resistance between As 2 O 3 and retinoids.
To investigate the mechanisms of RA resistance and to develop novel therapeutic drugs including As 2 O 3 a suitable in vivo model for human APL is urgent, however, no animal models of RA-resistant APL have been established. The transgenic models of acute leukemias will be invaluable in the study of the pathogenesis and new therapeutic approaches for this disease. Several transgenic mice have been developed for the PML/RAR␣ chimeric gene, the molecular basis for APL, but several important differences exist between the phenotypes of these early-model mice and humans. 23, 24 To resolve these problems, several groups have generated a cathepsin-G (CG) minigene expression vector and a human migration inhibitory factor-related protein (hMRP8) expression cassette which drive promyelocyte-specific expression of the targeted gene in mice. [25] [26] [27] Ten to 20% of the mice produced from PML/RAR␣ transgenic mice using either of these hCG and hMRP8 expression vectors developed with a long latency period to an acute myeloid leukemia characterized by features of APL and responded to retinoids. These approaches, however, take a long time to produce an APL model and yield only RA-sensitive APL mice. To make an RA-resistant APL model, therefore, we inoculated RA-resistant UF-1 cells into SCID mice. It has been reported that unexplained graft failures have been observed and that inoculation of myeloid leukemic cells into SCID mice have been generally unsuccessful. 28, 29 Therefore, we have established transgenic mice producing human GM-CSF with homozygous of scid gene, and resulting in highly reproducible engraftment of myeloid leukemic cells in mice. 30 By inoculating UF-1 cells into these hGM-CSF transgenic SCID mice, we successfully established the first RAresistant APL mouse model. 14 Our understanding of the mechanisms of cellular induction of apoptosis by As 2 O 3 in both RA-sensitive and RA-resistant APL cells will become increasingly important. Apoptosis is a genetic event, and many genes contribute to its regulation. The interaction between bcl-2 and other genes plays an important role in the induction of apoptosis. 31 It has been shown that BCL-2 can heterodimerize with several BCL-2-associated proteins, including BAX protein, which induces apoptosis of the cells. 32 As previously reported, 11 we demonstrated the downregulation of BCL-2 protein by the treatment of As 2 O 3 in NB4 cells. Interestingly, while As 2 O 3 had no influence on the expression of BCL-2 protein in UF-1 cells, it upregulated the levels of BAX protein in a dose-and timedependent manner. These results might meant that a lower ratio of BCL-2/BAX protein contributes to the As 2 O 3 -induced apoptosis in both RA-sensitive and RA-resistant APL cells. Because all-trans RA downregulates bcl-2 and fails to induce apoptosis, but can induce cellular differentiation, it is possible that a lower ratio of BCL-2/BAX may be the result rather than the cause, of As 2 O 3 -induced apoptosis in leukemic cells.
In the present in vivo studies using an RA-resistant APL model in hGMTgSCID mice, we demonstrated that As 2 O 3 can suppress the growth of subcutaneous tumors by inducing both apoptosis and differentiation of UF-1 cells. As distinct from in vitro studies, it remains unclear in the in vivo model why As 2 O 3 induces apoptosis and differentiation of UF-1 cells differently in different mouse. It has been reported in a study Leukemia of APL cells in vitro that As 2 O 3 could preferentially induce apoptosis at relatively higher concentrations (0.5-2 M), while inducing partial differentiation at lower concentrations (0.1-0.5 M).
12 Since the vascularity of tumors was changed in each mouse model, the local concentration and distribution of As 2 O 3 may be different in each experiment. Therefore, it is possible that in vivo As 2 O 3 administration causes both apoptosis and a partial differentiation of APL cells to mature granulocytes. Recent studies have reported that the combination of As 2 O 3 and all-trans RA enhanced differentiation and apoptosis in As 2 O 3 -resistant NB4 cells in vitro 33 and both chemicals together synergistically eradicated leukemic cells in the transgenic mouse model of APL. 34 The synergism between As 2 O 3 and all-trans RA could provide a novel therapeutic approach for APL, and the effects of both agents on our RAresistant APL mouse model will be interesting. The other possibility for differentiation of As 2 O 3 -treated UF-1 cells in vivo is that GM-CSF may have anti-apoptotic effects, resulting in the modulation of As 2 O 3 -induced apoptosis in RA-resistant APL cells. In fact, constitutive production of hGM-CSF does not reflect the human condition and a more extant model may be important to evaluate the therapeutic strategy for RA-resistant APL. However, we have demonstrated that the combination of GM-CSF and As 2 O 3 was potent in inducing differentiation of UF-1 cells in vitro, 35 suggesting that hGM-CSF may alter the response of UF-1 cells to As 2 O 3 in terms of promoting differentiation rather than apoptosis. Further studies will be needed to clarify the molecular mechanisms of cellular differentiation of leukemic cells in the treatment of both GM-CSF and As 2 O 3 . These two distinct effects of As 2 O 3 in vivo may account for its clinical advantages in the treatment of APL patients, including RA-resistant refractory cases.
In conclusion, As 2 O 3 can induce apoptosis and differentiation of both RA-sensitive and RA-resistant APL cells in vitro and in vivo. Our RA-resistant APL model in hGMTgSCID mice will be useful for evaluating novel therapeutic approaches, including As 2 O 3 therapy to patients with RA-resistant APL.
